ArcticZymes Technologies has signed an exclusive distribution agreement with Brenntag Specialties Pharma for the enzyme products SAN-HQ and M-SAN in Europe. Brenntag will be the exclusive distributor while ArcticZymes will maintain direct customer relationships. The products are used in gene therapy manufacturing, vaccine manufacturing and other advanced therapies. The agreement is part of ArcticZymes’ new channel strategy to increase the availability of the company’s salt-active nucleases in the European market.
|
Published October 29, 2025
ArcticZymes signs European distribution agreement
Text:
News Desk [email protected]
Notes
FluoGuide submits IND application for pivotal study in the US
Sigrid Therapeutics enters into global licensing agreement in oral health
NextCell Pharma proposes a private placement of SEK 15 million
GSK acquires RAPT Therapeutics in billion-dollar deal
Brain+ files for reorganization
Affibody raises SEK 307 million for investment in radioligand therapy
AstraZeneca directly lists common shares on NYSE
NEWSLETTER
Today's news roundup
News roundup Wednesday, January 21
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
Sprint Bioscience at J.P. Morgan Healthcare Week
The hunt for Nordic gems begins – LSI mobilizes 35 angels in new expansion
BioStock enters new chapter – Hanna Norrlid appointed CEO
J&J tops the list – here are the 5 biggest biopharma deals of 2025
Global data sees renewed optimism after tough year
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account